PRESS RELEASE
06 November 2026 09:00:00 CET

AcouSort extends collaboration with MFX through new project

AcouSort AB has received a new project order from MFX with a total value of EUR 9,500. The project builds on the existing collaboration between the companies and will evaluate AcouSort's acoustic cell washing technology at increased flow rates.

The project will investigate the feasibility of processing larger sample volumes using AcouSort's acoustofluidic technology. The study is a continuation of the AcouWash lease agreement initiated in Q1 2026 and focuses on optimizing cell isolation from lysed blood at higher flow rates. The project aims to provide further evidence of the potential for AcouSort's separation technology to meet the throughput requirements of full-scale production.

Increasing processing capacity is an important part of AcouSort's continued technology development and will broaden the range of applications and workflows that can benefit from automated acoustic sample preparation.

"We are pleased to continue our collaboration with MFX through this new project. Increasing throughput is an important development objective for AcouSort, and this study will allow us to further evaluate the potential of our technology for processing larger sample volumes," says Dr. Torsten Freltoft, CEO of AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: **torsten.freltoft@acousort.com**

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.